Agent for treating fabry disease, analgesic for external use and perspiration accelerator
The technology of a therapeutic agent and an enhancer is applied in the field of therapeutic agents for Fabry disease, which can solve the problems of unclear analgesic effect and the like, and achieve the effects of low concentration of active ingredients, safe treatment and simple use.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0085] Examples of methods for preparing external medicines include the following methods. (i) The gel can be prepared by gelling a solution containing rapamycin or a rapamycin derivative. (ii) An ointment can be prepared by mixing an ointment base with rapamycin or a rapamycin derivative. (iii) Patches, cataplasms, liniments, lotions, and creams can be prepared according to known methods.
[0086] Hereinafter, the gel and the ointment will be specifically described.
[0087] (I-A-1) Gel
[0088] As described above, the therapeutic agent for Fabry disease according to one embodiment of the present invention may be a gel obtained by gelling a solution containing rapamycin or a rapamycin derivative.
[0089] When gelling a solution containing rapamycin or a rapamycin derivative, it is only necessary to use a gelation inducer to gel the solution. Examples of gelation inducing agents include carboxyvinyl polymers, carboxymethylcellulose, aluminum hydroxide, bentonite and the l...
manufacture example
[0170] Production example: Preparation of gel containing rapamycin
[0171] Gels containing various concentrations of rapamycin were prepared. As a specific method, after adding and dissolving sirolimus (rapamycin) in ethanol, water (specifically, water for injection) was added and mixed to prepare a mixed solution. Carbopol (registered trademark) (specifically, Carbopol (registered trademark) 934P NF) was added to the mixed solution and mixed to prepare a homogeneous suspension. A neutralizer (specifically, tris) was added to the suspension and mixed to prepare a gel.
[0172] In addition, the components other than rapamycin in 1 g of the gel are 16 mg of Carbopol (registered trademark) 934PNF, 490 mg of water, 480-490 mg of ethanol, and 6 mg of tris.
[0173] More specifically, gels were prepared with the compositions of Production Examples 1 and 2 and Comparative Production Example 1 below.
manufacture example 1
[0174] Production Example 1: Gel containing 0.4% by weight of rapamycin (total weight 100 g)
[0175] Rapamycin 0.4g
[0176] Ethanol 48.4g
[0177] Water for injection 49g
[0178] Carbopol (registered trademark) 934P NF 1.6g
[0179] Trishydroxymethylaminomethane 0.6g.
PUM
Property | Measurement | Unit |
---|---|---|
concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com